RCC
MCID: RNL114
MIFTS: 79

Renal Cell Carcinoma, Nonpapillary (RCC)

Categories: Cancer diseases, Genetic diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Renal Cell Carcinoma, Nonpapillary

MalaCards integrated aliases for Renal Cell Carcinoma, Nonpapillary:

Name: Renal Cell Carcinoma, Nonpapillary 56 29 6
Renal Cell Carcinoma 56 12 74 52 58 73 36 15 17 71
Adenocarcinoma of Kidney 56 12 52 73
Rcc 56 12 58 73
Hypernephroma 56 12 73
Hereditary Clear Cell Renal Cell Carcinoma 58 71
Renal Carcinoma, Chromophobe, Somatic 56 13
Nonpapillary Renal Cell Carcinoma 12 15
Clear Cell Renal Carcinoma 73 17
Renal Cell Adenocarcinoma 52 17
Carcinoma, Renal Cell 43 39
Hereditary Clear Cell Renal Cell Adenocarcinoma 58
Renal Cell Carcinoma, Clear Cell, Somatic 56
Conventional Renal Cell Carcinoma 71
Carcinoma, Renal Cell, Nonpapillary 39
Renal Cell Carcinoma Non-Papillary 73
Conventional Renal Cell Carcinoma 73
Renal Cell Carcinoma, Somatic 56
Common Renal Cell Carcinoma 73
Carcinoma Renal Cell 54
Renal Cell Cancer 15
Ccrcc 73
Crcc 73

Characteristics:

Orphanet epidemiological data:

58
renal cell carcinoma
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe); Age of onset: Adult;

HPO:

31
renal cell carcinoma, nonpapillary:
Inheritance sporadic


Classifications:

Orphanet: 58  
Rare renal diseases


External Ids:

Disease Ontology 12 DOID:0050387 DOID:4450
OMIM 56 144700
KEGG 36 H00021
MeSH 43 D002292
NCIt 49 C9385
SNOMED-CT 67 41607009
MESH via Orphanet 44 D002292
ICD10 via Orphanet 33 C64
UMLS via Orphanet 72 C0007134
SNOMED-CT via HPO 68 702391001
UMLS 71 C0007134 C0279702 C1333985

Summaries for Renal Cell Carcinoma, Nonpapillary

OMIM : 56 The Heidelberg histologic classification of renal cell tumors subdivides renal cell tumors into benign and malignant parenchymal neoplasms and, where possible, limits each subcategory to the most common documented genetic abnormalities (Kovacs et al., 1997). Malignant tumors are subclassified into common or conventional renal cell carcinoma (clear cell); papillary renal cell carcinoma; chromophobe renal cell carcinoma; collecting duct carcinoma, with medullary carcinoma of the kidney; and unclassified renal cell carcinoma. The common or conventional type accounts for about 75% of renal cell neoplasms and is characterized genetically by a highly specific deletion of chromosome 3p. Papillary renal cell carcinoma (see 605074) accounts for about 10% of renal cell tumors. Chromophobe renal cell carcinoma accounts for approximately 5% of renal cell neoplasms. Genetically, chromophobe RCC is characterized by a combination of loss of heterozygosity of chromosomes 1, 2, 6, 10, 13, 17, and 21 and hypodiploid DNA content. Collecting duct carcinoma accounts for about 1% of renal cell carcinoma. Renal cell carcinoma occurs nearly twice as often in men as in women; incidence in the United States is equivalent among whites and blacks. Cigarette smoking doubles the likelihood of renal cell carcinoma and contributes to as many as one-third of cases. Obesity is also a risk factor, particularly in women. Other risk factors include hypertension, unopposed estrogen therapy, and occupational exposure to petroleum products, heavy metals, or asbestos (summary by Motzer et al., 1996). (144700)

MalaCards based summary : Renal Cell Carcinoma, Nonpapillary, also known as renal cell carcinoma, is related to hereditary renal cell carcinoma and kidney cancer, and has symptoms including flank pain An important gene associated with Renal Cell Carcinoma, Nonpapillary is FLCN (Folliculin), and among its related pathways/superpathways are Renal cell carcinoma and Transcriptional misregulation in cancer. The drugs Fentanyl and Midazolam have been mentioned in the context of this disorder. Affiliated tissues include kidney, lung and endothelial, and related phenotypes are renal cell carcinoma and Decreased sensitivity to paclitaxel

Disease Ontology : 12 A renal carcinoma that has material basis in the lining of the proximal convoluted renal tubule of the kidney.

KEGG : 36 Renal cell cancer (RCC) accounts for ~3% of human malignancies and its incidence appears to be rising. Although most cases of RCC seem to occur sporadically, an inherited predisposition to renal cancer accounts for 1-4% of cases. RCC is not a single disease, it has several morphological subtypes. Conventional RCC (clear cell RCC) accounts for ~80% of cases, followed by papillary RCC (10-15%), chromophobe RCC (5%), and collecting duct RCC (<1%). Genes potentially involved in sporadic neoplasms of each particular type are VHL, MET, BHD, and FH respectively. In the absence of VHL, hypoxia-inducible factor alpha (HIF-alpha) accumulates, leading to production of several growth factors, including vascular endothelial growth factor and platelet-derived growth factor. Activated MET mediates a number of biological effects including motility, invasion of extracellular matrix, cellular transformation, prevention of apoptosis and metastasis formation. Loss of functional FH leads to accumulation of fumarate in the cell, triggering inhibition of HPH and preventing targeted pVHL-mediated degradation of HIF-alpha. BHD mutations cause the Birt-Hogg-Dube syndrome and its associated chromophobe, hybrid oncocytic, and conventional (clear cell) RCC.

UniProtKB/Swiss-Prot : 73 Renal cell carcinoma: Renal cell carcinoma is a heterogeneous group of sporadic or hereditary carcinoma derived from cells of the proximal renal tubular epithelium. It is subclassified into clear cell renal carcinoma (non- papillary carcinoma), papillary renal cell carcinoma, chromophobe renal cell carcinoma, collecting duct carcinoma with medullary carcinoma of the kidney, and unclassified renal cell carcinoma. Clear cell renal cell carcinoma is the most common subtype.

Wikipedia : 74 Renal cell carcinoma (RCC) is a kidney cancer that originates in the lining of the proximal convoluted... more...

Related Diseases for Renal Cell Carcinoma, Nonpapillary

Diseases related to Renal Cell Carcinoma, Nonpapillary via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1280)
# Related Disease Score Top Affiliating Genes
1 hereditary renal cell carcinoma 35.6 RNF139 MET FLCN FHIT
2 kidney cancer 35.4 VHL TP53 SETD2 RNF139 PTEN PIK3CA
3 clear cell renal cell carcinoma 35.2 VHL TP53 SETD2 RNF139 PTEN OGG1
4 chromophobe renal cell carcinoma 35.1 VHL SETD2 RNF139 OGG1 MIR200C HNF1B
5 clear cell papillary renal cell carcinoma 34.9 VHL HNF1A
6 renal cell carcinoma, papillary, 1 34.8 VHL TP53 SETD2 PTEN PIK3CA NRAS
7 birt-hogg-dube syndrome 33.8 PTEN MTOR FLCN
8 cowden syndrome 1 33.6 PTEN PIK3CA MTOR
9 lung cancer susceptibility 3 32.9 TP53 SETD2 PTEN PIK3CA OGG1 NRAS
10 melanoma 32.9 TP53 PTEN PIK3CA NRAS MTOR MIR200C
11 colorectal cancer 32.8 TP53 SETD2 PTEN PIK3CA OGG1 NRAS
12 neuroblastoma 32.8 TP53 PTEN PIK3CA NRAS MTOR MET
13 lung cancer 32.7 VHL TP53 SETD2 PTEN PIK3CA OGG1
14 pancreatic cancer 32.7 TP53 PTEN PIK3CA MTOR MIR200C MIR141
15 esophageal cancer 32.5 TP53 PTEN PIK3CA OGG1 MTOR MIR200C
16 lymphoma, non-hodgkin, familial 32.4 TP53 PTEN PIK3CA NRAS MTOR ATM
17 cholangiocarcinoma 32.3 TP53 PTEN PIK3CA OGG1 MTOR MIR141
18 gastric cancer 32.2 TP53 PTEN PIK3CA OGG1 NRAS MTOR
19 thyroid tumor 32.1 TP53 PTEN PIK3CA NRAS
20 tuberous sclerosis 32.1 VHL TP53 PTEN PIK3CA MTOR FLCN
21 ovarian clear cell carcinoma 32.1 TP53 PTEN PIK3CA MET HNF1B
22 glioblastoma multiforme 32.1 TP53 PTEN PIK3CA NRAS MTOR MET
23 nasopharyngeal carcinoma 32.0 TP53 PTEN PIK3CA NRAS MTOR MIR141
24 suppression of tumorigenicity 12 32.0 TP53 PTEN PIK3CA MTOR ATM
25 adrenocortical carcinoma, hereditary 32.0 TP53 PIK3CA NRAS
26 collecting duct carcinoma 31.9 VHL SETD2 FLCN FHIT
27 pancreatic adenocarcinoma 31.9 TP53 PTEN PIK3CA MET ATM
28 lynch syndrome 31.9 TP53 PTEN PIK3CA OGG1 NRAS FLCN
29 lung squamous cell carcinoma 31.9 TP53 PTEN PIK3CA OGG1 MTOR MET
30 myeloma, multiple 31.9 TP53 PTEN NRAS MTOR MET ATM
31 chordoma 31.9 TP53 PTEN MTOR MET
32 cystic kidney disease 31.8 VHL MTOR HNF1B FLCN
33 cowden syndrome 31.8 TP53 PTEN PIK3CA MTOR FLCN ATM
34 gastric adenocarcinoma 31.8 TP53 PTEN PIK3CA NRAS MTOR MET
35 squamous cell carcinoma, head and neck 31.8 TP53 SETD2 PTEN PIK3CA OGG1 MIR141
36 glioma 31.8 TP53 PTEN PIK3CA MET ATM
37 mantle cell lymphoma 31.8 TP53 PTEN PIK3CA MTOR ATM
38 bladder urothelial carcinoma 31.8 TP53 PTEN PIK3CA NRAS MTOR FHIT
39 gallbladder cancer 31.7 TP53 PTEN PIK3CA FHIT
40 bladder cancer 31.7 TP53 PTEN PIK3CA OGG1 NRAS MIR141
41 adenoid cystic carcinoma 31.7 TP53 PTEN PIK3CA MTOR ATM
42 ovarian clear cell adenocarcinoma 31.7 TP53 PIK3CA MTOR MET HNF1B
43 melanoma, uveal 31.6 TP53 PTEN NRAS MET
44 sarcoma 31.6 TP53 PIK3CA NRAS MTOR MET
45 medulloblastoma 31.6 TP53 PTEN PIK3CA NRAS MTOR MET
46 cervical cancer 31.6 TP53 PTEN PIK3CA MTOR MIR141 FHIT
47 testicular germ cell tumor 31.6 TP53 PTEN MIR200C
48 differentiated thyroid carcinoma 31.6 TP53 NRAS MET FHIT DIRC3 ATM
49 thyroid carcinoma 31.5 TP53 PTEN PIK3CA NRAS
50 neurofibromatosis, type iv, of riccardi 31.5 VHL TP53 PTEN MTOR

Graphical network of the top 20 diseases related to Renal Cell Carcinoma, Nonpapillary:



Diseases related to Renal Cell Carcinoma, Nonpapillary

Symptoms & Phenotypes for Renal Cell Carcinoma, Nonpapillary

Human phenotypes related to Renal Cell Carcinoma, Nonpapillary:

31
# Description HPO Frequency HPO Source Accession
1 renal cell carcinoma 31 HP:0005584

Clinical features from OMIM:

144700

UMLS symptoms related to Renal Cell Carcinoma, Nonpapillary:


flank pain

GenomeRNAi Phenotypes related to Renal Cell Carcinoma, Nonpapillary according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased sensitivity to paclitaxel GR00112-A-0 8.62 PTEN VHL

MGI Mouse Phenotypes related to Renal Cell Carcinoma, Nonpapillary:

45 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.29 ATM FLCN HNF1A MET MTOR NRAS
2 homeostasis/metabolism MP:0005376 10.25 ATM FHIT FLCN HNF1A HNF1B MET
3 embryo MP:0005380 10.24 ATM FLCN HNF1B MET MTOR NRAS
4 immune system MP:0005387 10.24 ATM FHIT FLCN HNF1B HSPBAP1 MET
5 growth/size/body region MP:0005378 10.23 ATM FLCN HNF1A HNF1B MET MTOR
6 cardiovascular system MP:0005385 10.22 ATM FLCN MET MTOR NRAS PIK3CA
7 endocrine/exocrine gland MP:0005379 10.18 ATM HNF1A HNF1B MET MTOR NRAS
8 hematopoietic system MP:0005397 10.17 ATM FHIT FLCN HSPBAP1 MTOR NRAS
9 mortality/aging MP:0010768 10.1 ATM FHIT FLCN HNF1A HNF1B MET
10 adipose tissue MP:0005375 10.08 ATM HNF1A MTOR PIK3CA PTEN SETD2
11 liver/biliary system MP:0005370 9.97 HNF1A HNF1B MET NRAS OGG1 PTEN
12 muscle MP:0005369 9.76 HNF1A HNF1B MET MTOR PIK3CA PTEN
13 neoplasm MP:0002006 9.7 ATM FHIT FLCN MET NRAS OGG1
14 renal/urinary system MP:0005367 9.23 FLCN HNF1A HNF1B MET MTOR PTEN

Drugs & Therapeutics for Renal Cell Carcinoma, Nonpapillary

Drugs for Renal Cell Carcinoma, Nonpapillary (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 466)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
2
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
3
Caffeine Approved Phase 4 58-08-2 2519
4
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
5
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
6
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
7
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
8
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
9
Nicotine Approved Phase 4 54-11-5 942 89594
10
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
11
Sorafenib Approved, Investigational Phase 4 284461-73-0 216239 406563
12 Neurotransmitter Agents Phase 4
13 Anesthetics, Local Phase 4
14 Anesthetics Phase 4
15 Central Nervous System Depressants Phase 4
16 Anesthetics, General Phase 4
17 Autonomic Agents Phase 4
18 Adrenergic Agents Phase 4
19 Platelet Aggregation Inhibitors Phase 4
20 Adjuvants, Anesthesia Phase 4
21 Narcotics Phase 4
22 Analgesics, Opioid Phase 4
23 Adrenergic Agonists Phase 4
24 Hypnotics and Sedatives Phase 4
25 Central Nervous System Stimulants Phase 4
26 Tranquilizing Agents Phase 4
27 Psychotropic Drugs Phase 4
28 GABA Agents Phase 4
29 Phosphodiesterase Inhibitors Phase 4
30 Anesthetics, Intravenous Phase 4
31 GABA Modulators Phase 4
32 Cholinergic Agents Phase 4
33 Anesthetics, Inhalation Phase 4
34 Adrenergic alpha-2 Receptor Agonists Phase 4
35 Dopamine Agents Phase 4
36 Nicotinic Agonists Phase 4
37 Dopamine Uptake Inhibitors Phase 4
38 Antidepressive Agents Phase 4
39 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
40 Protein Kinase Inhibitors Phase 4
41 Liver Extracts Phase 4
42 Pharmaceutical Solutions Phase 4
43
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
44
Clonidine Approved Phase 2, Phase 3 4205-90-7 2803
45
Medroxyprogesterone acetate Approved, Investigational Phase 3 71-58-9
46
Diphenhydramine Approved, Investigational Phase 3 58-73-1, 147-24-0 3100
47
Promethazine Approved, Investigational Phase 3 60-87-7 4927
48
Dactinomycin Approved, Investigational Phase 3 50-76-0 2019 457193
49
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
50
Ethanol Approved Phase 3 64-17-5 702

Interventional clinical trials:

(show top 50) (show all 1609)
# Name Status NCT ID Phase Drugs
1 Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors Unknown status NCT00777504 Phase 4 usage oral angiogenesis inhibitor;stop oral angiogenesis inhibitor
2 An Open Label, Single Arm Trial to Characterize Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of the First VEGF-targeted Therapy Completed NCT01266837 Phase 4 Everolimus
3 A Single-Arm, Open-Label, Multi-Center, Phase Iv, Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma (Post Approval Commitment Study) Completed NCT00706706 Phase 4 Sunitinib Malate (SU011248)
4 Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis Completed NCT00172003 Phase 4 Zoledronic acid
5 Interleukin-2 In An Alternative Dose (The Iliad Trial): Treatment Of Patients With Metastatic Renal Cell Carcinoma With Low Dose Proleukin Completed NCT00006864 Phase 4
6 An Open Label, Single Arm Trial to Evaluate Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of First Line Therapy With Sunitinib or Pazopanib Completed NCT01514448 Phase 4 Everolimus (RAD001)
7 An Open-label, Multi-center Phase 2 Study to Evaluate Everolimus as Monotherapy Treatment for Patients With Metastatic Recurrent and/or Unresectable Renal Cell Carcinoma (EVERMORE). Completed NCT01206764 Phase 4 RAD001
8 A Single Arm Multicentre Study Evaluating Pazopanib in First-line Treatment of Poor-risk Patients With Locally Advanced or Metastatic Renal Cell Carcinoma Completed NCT01521715 Phase 4 Pazopanib
9 Everolimus (Afinitor) in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment Completed NCT02056587 Phase 4 Everolimus
10 Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients Completed NCT01402089 Phase 4 Sunitinib;Erlotinib;Midazolam;Caffeine
11 Immunomodulatory Effects of Volatile and Total Intravenous Anesthesia for Patients With Renal Cancer Completed NCT03514550 Phase 4 Propofol;Sevoflurane
12 Effects of Dexmedetomidine on Periprocedural Pain During Radiofrequency Ablation of Liver and Kidney Tumours Completed NCT02016391 Phase 4 Dexmedetomidine
13 Evaluation of Cardiac Arrhythmias in Patients Undergoing Kidney Cancer Surgery Depending on the Anaesthesia Method Completed NCT02988219 Phase 4 Bupivacaine-fentanyl
14 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
15 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride
16 ICE-SECRET PROSENSE™ Cryotherapy For Renal Cell Carcinoma Trial Recruiting NCT02399124 Phase 4
17 Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma Recruiting NCT02733809 Phase 4 Sorafenib
18 Phase 3b/4 Safety Trial of Nivolumab Combined With Ipilimumab in Subjects With Previously Untreated, Advanced or Metastatic RCC (CheckMate 920: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 920) Active, not recruiting NCT02982954 Phase 4 Nivolumab;Ipilimumab
19 Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma Active, not recruiting NCT02555748 Phase 4 Pazopanib;Sunitinib
20 A Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374) Active, not recruiting NCT02596035 Phase 4 Nivolumab
21 A Proof of Concept Study to Evaluate the Use of Metabonomics and Lipidomics in Predicting Toxicity and Efficacy of Anti-VEGF Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma Active, not recruiting NCT02570789 Phase 4 patients with sunitinib or pazopanib
22 Correlation of Contrast Enhanced Ultrasound of Renal Masses With Pathologic Grade: A Prospective Comparison of Quantitative and Qualitative Findings Not yet recruiting NCT03821376 Phase 4 Contrast enhanced ultrasound with Lumason
23 Contrast-Enhanced Ultrasound for Kidney Cancer Subtyping and Staging Not yet recruiting NCT04021238 Phase 4 Perflutren lipid microsphere;Sulfur hexafluoride lipid microspheres
24 A Randomized Discontinuation Trial to Determine the Clinical Benefit of Continuation of Sorafenib Following Disease Progression in Patients With Advanced Renal Cell Carcinoma Terminated NCT00352859 Phase 4 Nexavar (Sorafenib, BAY43-9006) with addition of gemcitabine or interferon;Gemcitabine or Interferon (only)
25 Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of a First-line Treatment With VEGF Inhibitor Terminated NCT02338570 Phase 4 Everolimus
26 A Study of Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma With Sunitinib BEFORE and AFTER Nephrectomy Terminated NCT00930345 Phase 4 Sunitinib (SUTENT)
27 Effects of Physical Activity on the Endothelial and Cardiac Function of Patients With Renal Cell Carcinoma Receiving a Thyrosine Kinase Inhibitor (Sunitinib) Unknown status NCT00869011 Phase 3
28 Randomized Phase III Trial Comparing Immediate Versus Deferred Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Unknown status NCT01099423 Phase 3
29 Randomized Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma Unknown status NCT01481870 Phase 3 Sorafenib-sunitinib;Sunitinib-sorafenib
30 Minocycline Attenuate Postoperative Cognitive Dysfunction and Delirium: A Multicenter, Randomized, Double-Blind Clinical Trail Unknown status NCT02928692 Phase 3 Minocycline;Placebo
31 Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex Unknown status NCT01730209 Phase 2, Phase 3 Everolimus;Placebo
32 A Comparative Study of PET/CT Versus Diagnostic CT for the Detection of Clear Cell Renal Cell Carcinoma in Pre-surgical Patients With Renal Masses Using Iodine-124 Labeled Chimeric G250 (124I-cG250) Completed NCT00606632 Phase 3 124-Iodine-cG250 (124I-cG250)
33 A Randomised, Double-blind Study to Evaluate the Efficacy and Safety of Avastin Plus Roferon Compared With Placebo Plus Roferon on Overall Survival and Tumor Assessment in Nephrectomised Patients With Metastatic Clear Cell Renal Cell Carcinoma Completed NCT00738530 Phase 3 Bevacizumab [Avastin];Interferon alfa 2a [Roferon];Placebo
34 A Multicenter Uncontrolled Study of Sorafenib in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma Completed NCT00586105 Phase 3 Sorafenib (Nexavar, BAY43-9006)
35 An Open Label, Non Comparative, Phase III Study of the Raf Kinase Inhibitor BAY 43-9006 as a Subsequent to First Line Therapy in Patients With Advanced Renal Cell Carcinoma Completed NCT00492986 Phase 3 Nexavar (Sorafenib, BAY43-9006)
36 Adjuvant Low-dose Interleukin-2 (IL2) Plus Interferone-alpha (IFN) in Operable Renal Cell Cancer (RCC). Phase III, Randomized, Multicenter Trial of the Italian Oncology Group for Clinical Research (GOIRC). Completed NCT00502034 Phase 3 Interferon Alfa-2a;Interleukin-2
37 SORCE: A Phase III Randomised Double-Blind Study Comparing Sorafenib With Placebo in Patients With Resected Primary Renal Cell Carcinoma at High or Intermediate Risk of Relapse Completed NCT00492258 Phase 3 sorafenib tosylate
38 A Randomized Controlled Phase III Adjuvant Trial of High-Dose Bolus IL-2 in Patients With High-Risk Renal Cell Carcinoma Completed NCT00003126 Phase 3 Interleukin-2
39 A Phase 3, Randomized Study Of SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma Completed NCT00083889 Phase 3 Interferon-alfa;SU011248
40 A Phase III Randomized Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer. Completed NCT00073307 Phase 3 Sorafenib (Nexavar, BAY43-9006);Placebo
41 An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies Completed NCT01223027 Phase 3 Dovitinib;Sorafenib
42 Dynamic-Contrast Enhanced MRI Pharmacodynamic Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma Completed NCT00606866 Phase 3 placebo;Sorafenib;Sorafenib
43 A Prospective Randomized Phase III Study Comparing Radical Surgery to Elective Kidney Sparing Surgery for Low Stage Renal Cell Carcinoma Completed NCT00002473 Phase 3
44 Phase 3b, Randomized, Open-Label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-Alfa As First-Line Treatment In Subjects With Advanced Renal Cell Carcinoma Completed NCT00631371 Phase 3 Bevacizumab;Temsirolimus;Bevacizumab;Interferon-Alfa 9MU
45 AE-941 (NEOVASTAT) Versus Placebo in Metastatic Renal Cell Carcinoma Patients Who Are Refractory to Immunotherapy Completed NCT00005995 Phase 3 shark cartilage extract AE-941
46 Phase III Randomized Study of Intravenous Low Dose Versus Intravenous High Dose Versus Subcutaneous Interleukin-2 for Metastatic Renal Cell Carcinoma Completed NCT00018941 Phase 3
47 A Randomized Phase III Trial Of Interferon Alfa-2B Or Interferon Alfa-2B Plus Bevacizumab In Patients With Advanced Renal Carcinoma Completed NCT00072046 Phase 3
48 A RANDOMIZED PHASE II TRIAL OF INTERFERON ALPHA-2A WITH AND WITHOUT 13-CIS RETINOIC ACID IN PATIENTS WITH PROGRESSIVE MEASURABLE METASTATIC RENAL CELL CARCINOMA. Amendment Protocol: Extension to a Randomized Phase III Trial Completed NCT00002737 Phase 3 chemotherapy;isotretinoin
49 AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL Completed NCT00678392 Phase 3 Axitinib (AG-013736);Sorafenib
50 A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER) Completed NCT00087022 Phase 3

Search NIH Clinical Center for Renal Cell Carcinoma, Nonpapillary

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Aldesleukin
axitinib
cabozantinib
hydroxyurea
Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
Interferons
lenvatinib
Medroxyprogesterone
medroxyprogesterone acetate
peginterferon alfa-2a
peginterferon alfa-2b
Recombinant interferon beta-1a
Recombinant interferon beta-1b
sorafenib
sunitinib
sunitinib malate
temsirolimus
Thalidomide

Cochrane evidence based reviews: carcinoma, renal cell

Genetic Tests for Renal Cell Carcinoma, Nonpapillary

Genetic tests related to Renal Cell Carcinoma, Nonpapillary:

# Genetic test Affiliating Genes
1 Renal Cell Carcinoma, Nonpapillary 29 FLCN HNF1A HNF1B OGG1 RNF139 SLC49A4 VHL

Anatomical Context for Renal Cell Carcinoma, Nonpapillary

MalaCards organs/tissues related to Renal Cell Carcinoma, Nonpapillary:

40
Kidney, Lung, Endothelial, Bone, Brain, Thyroid, T Cells

Publications for Renal Cell Carcinoma, Nonpapillary

Articles related to Renal Cell Carcinoma, Nonpapillary:

(show top 50) (show all 30700)
# Title Authors PMID Year
1
Germline hepatocyte nuclear factor 1alpha and 1beta mutations in renal cell carcinomas. 56 6 54 61
15649945 2005
2
A germline mutation in PBRM1 predisposes to renal cell carcinoma. 56 6 61
25911086 2015
3
Integrated molecular analysis of clear-cell renal cell carcinoma. 56 61
23797736 2013
4
Comprehensive molecular characterization of clear cell renal cell carcinoma. 56 61
23792563 2013
5
BAP1 loss defines a new class of renal cell carcinoma. 61 56
22683710 2012
6
Paraganglioma, neuroblastoma, and a SDHB mutation: Resolution of a 30-year-old mystery. 61 56
20503330 2010
7
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. 61 56
20054297 2010
8
Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c. 54 61 46
18925646 2008
9
External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. 56 61
18260086 2008
10
A constitutional balanced t(3;8)(p14;q24.1) translocation results in disruption of the TRC8 gene and predisposition to clear cell renal cell carcinoma. 61 56
17539022 2007
11
Loss of the actin regulator HSPC300 results in clear cell renal cell carcinoma protection in Von Hippel-Lindau patients. 56 61
17311301 2007
12
B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. 61 56
16798883 2006
13
Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. 61 56
16814207 2006
14
Cloning of a new familial t(3;8) translocation associated with conventional renal cell carcinoma reveals a 5 kb microdeletion and no gene involved in the rearrangement. 61 56
15016767 2004
15
Upregulation of the transcription factor TFEB in t(6;11)(p21;q13)-positive renal cell carcinomas due to promoter substitution. 54 56
12837690 2003
16
The allelic loss of chromosome 3p25 with c-myc gain is related to the development of clear-cell renal cell carcinoma. 56 61
12694227 2003
17
Understanding familial and non-familial renal cell cancer. 56 61
12351585 2002
18
Molecular analysis of a familial case of renal cell cancer and a t(3;6)(q12;q15). 56 54
11284032 2001
19
Familial clear cell renal cell carcinoma (FCRC): clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes. 61 56
10807693 2000
20
The genetic locus NRC-1 within chromosome 3p12 mediates tumor suppression in renal cell carcinoma independently of histological type, tumor microenvironment, and VHL mutation. 61 56
10232606 1999
21
The hereditary renal cell carcinoma 3;8 translocation fuses FHIT to a patched-related gene, TRC8. 56 61
9689122 1998
22
Physical and functional mapping of a tumor suppressor locus for renal cell carcinoma within chromosome 3p12. 61 56
9721855 1998
23
An alternative route for multistep tumorigenesis in a novel case of hereditary renal cell cancer and a t(2;3)(q35;q21) chromosome translocation. 61 56
9585616 1998
24
A familial case of renal cell carcinoma and a t(2;3) chromosome translocation. 56 61
9461085 1998
25
The Heidelberg classification of renal cell tumours. 56 61
9390023 1997
26
Renal-cell carcinoma. 61 56
8778606 1996
27
A tumor suppressor locus within 3p14-p12 mediates rapid cell death of renal cell carcinoma in vivo. 61 56
8159756 1994
28
Hereditary renal cell carcinoma in the Eker rat: a rodent familial cancer syndrome. 56 61
1433648 1992
29
Allelic losses at chromosome 17p in human renal cell carcinoma are inversely related to allelic losses at chromosome 3p. 61 56
1348014 1992
30
Predisposition to renal cell carcinoma due to alteration of a cancer susceptibility gene. 56 61
1553556 1992
31
Molecular and cellular characterization of human renal cell carcinoma cell lines. 56 61
1345811 1992
32
The region of common allelic losses in sporadic renal cell carcinoma is bordered by the loci D3S2 and THRB. 61 56
1685475 1991
33
Allelic loss at chromosome 3p characterizes clear cell phenotype of renal cell carcinoma. 61 56
1671000 1991
34
Familial renal cell carcinoma: hereditary or coincidental? 56 61
2398557 1990
35
Introduction of normal chromosome 3p modulates the tumorigenicity of a human renal cell carcinoma cell line YCR. 56 61
1969617 1990
36
A 1.5-megabase restriction map surrounding MYC does not include the translocation breakpoint in familial renal cell carcinoma. 61 56
2914707 1989
37
Do human renal cell carcinomas arise by a double-loss mechanism? 61 56
3203309 1988
38
Recurrent genomic rearrangements are not at the fragile sites on chromosomes 3 and 5 in human renal cell carcinomas. 61 56
3417313 1988
39
Genomic defects in nonfamilial renal cell carcinoma. Possible specific chromosome change. 61 56
3395987 1988
40
Direct molecular analysis of a deletion of 3p in tumors from patients with sporadic renal cell carcinoma. 61 56
2835149 1988
41
Consistent chromosome 3p deletion and loss of heterozygosity in renal cell carcinoma. 56 61
2894030 1988
42
Loss of der(3) in renal carcinoma cells of a patient with constitutional t(3;12). 56 61
3422215 1988
43
Specific chromosome aberration in human renal cell carcinoma. 56 61
3610386 1987
44
Proximal 3p deletion in renal cell carcinoma cells from a patient with von Hippel-Lindau disease. 56 61
3594418 1987
45
Deletion 3p: the only chromosome loss in a primary renal cell carcinoma. 61 56
3567881 1987
46
Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. 61 56
2885753 1987
47
Recurrent deletion of the short arm of chromosome 3 in human renal cell carcinoma: shift of the c-raf 1 locus. 56 61
3467112 1986
48
Rearrangement of chromosome 3 in renal cell carcinoma. 56 61
3943052 1986
49
Specific chromosome anomalies and predisposition to human breast, renal cell, and colorectal carcinoma. 56 61
3940177 1986
50
Involvement of band 3p14 in t(3;8) hereditary renal carcinoma. 61 56
6704944 1984

Variations for Renal Cell Carcinoma, Nonpapillary

ClinVar genetic disease variations for Renal Cell Carcinoma, Nonpapillary:

6 (show top 50) (show all 803) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 CTNNB1 NM_001904.4(CTNNB1):c.1374A>C (p.Glu458Asp)SNV other 438755 rs1553631848 3:41275208-41275208 3:41233717-41233717
2 HNF1A NM_000545.6(HNF1A):c.814C>T (p.Arg272Cys)SNV Pathogenic 447503 rs1555212014 12:121432067-121432067 12:120994264-120994264
3 TP53 NM_000546.5(TP53):c.841G>T (p.Asp281Tyr)SNV Pathogenic 376585 rs764146326 17:7577097-7577097 17:7673779-7673779
4 TP53 NM_000546.5(TP53):c.841G>A (p.Asp281Asn)SNV Pathogenic 376586 rs764146326 17:7577097-7577097 17:7673779-7673779
5 VHL NM_000551.3(VHL):c.548C>A (p.Ser183Ter)SNV Pathogenic 2215 rs5030823 3:10191555-10191555 3:10149871-10149871
6 VHL NM_000551.3(VHL):c.481C>T (p.Arg161Ter)SNV Pathogenic 2217 rs5030818 3:10191488-10191488 3:10149804-10149804
7 VHL NM_000551.3(VHL):c.499C>T (p.Arg167Trp)SNV Pathogenic 2218 rs5030820 3:10191506-10191506 3:10149822-10149822
8 ATM ATM, IVS61DS, 2-BP INS, +2TAinsertion Pathogenic 3037
9 PTEN NM_000314.7(PTEN):c.389G>A (p.Arg130Gln)SNV Pathogenic 7829 rs121909229 10:89692905-89692905 10:87933148-87933148
10 TP53 NM_000546.5(TP53):c.659A>C (p.Tyr220Ser)SNV Pathogenic 12383 rs121912666 17:7578190-7578190 17:7674872-7674872
11 PIK3CA NM_006218.4(PIK3CA):c.3140A>G (p.His1047Arg)SNV Pathogenic 13652 rs121913279 3:178952085-178952085 3:179234297-179234297
12 PIK3CA NM_006218.4(PIK3CA):c.3140A>T (p.His1047Leu)SNV Pathogenic 13653 rs121913279 3:178952085-178952085 3:179234297-179234297
13 PIK3CA NM_006218.4(PIK3CA):c.1634A>C (p.Glu545Ala)SNV Pathogenic 13659 rs121913274 3:178936092-178936092 3:179218304-179218304
14 MET NM_001127500.3(MET):c.3446T>C (p.Met1149Thr)SNV Pathogenic 13881 rs121913668 7:116418881-116418881 7:116778827-116778827
15 MET NM_001127500.3(MET):c.3616G>T (p.Val1206Leu)SNV Pathogenic 13882 rs121913669 7:116422081-116422081 7:116782027-116782027
16 MET NM_001127500.3(MET):c.3712G>A (p.Val1238Ile)SNV Pathogenic 13883 rs121913670 7:116423383-116423383 7:116783329-116783329
17 MET NM_001127500.3(MET):c.3637C>G (p.Leu1213Val)SNV Pathogenic 13886 rs121913673 7:116422102-116422102 7:116782048-116782048
18 MET NM_001127500.3(MET):c.3335A>G (p.His1112Arg)SNV Pathogenic 13887 rs121913243 7:116417464-116417464 7:116777410-116777410
19 NRAS NM_002524.5(NRAS):c.182A>G (p.Gln61Arg)SNV Pathogenic 13900 rs11554290 1:115256529-115256529 1:114713908-114713908
20 HNF1A NM_000545.6(HNF1A):c.1340C>T (p.Pro447Leu)SNV Pathogenic 14928 rs137853236 12:121435307-121435307 12:120997504-120997504
21 PIK3CA NM_006218.4(PIK3CA):c.3139C>T (p.His1047Tyr)SNV Pathogenic 39705 rs121913281 3:178952084-178952084 3:179234296-179234296
22 TP53 NM_000546.5(TP53):c.659A>G (p.Tyr220Cys)SNV Pathogenic 127819 rs121912666 17:7578190-7578190 17:7674872-7674872
23 TP53 NM_000546.5(TP53):c.638G>A (p.Arg213Gln)SNV Pathogenic 135359 rs587778720 17:7578211-7578211 17:7674893-7674893
24 TP53 NM_000546.5(TP53):c.422G>A (p.Cys141Tyr)SNV Pathogenic 140801 rs587781288 17:7578508-7578508 17:7675190-7675190
25 TP53 NM_000546.5(TP53):c.844C>G (p.Arg282Gly)SNV Pathogenic 140821 rs28934574 17:7577094-7577094 17:7673776-7673776
26 TP53 NM_000546.5(TP53):c.842A>G (p.Asp281Gly)SNV Pathogenic 141141 rs587781525 17:7577096-7577096 17:7673778-7673778
27 MET NM_001127500.3(MET):c.3328G>A (p.Val1110Ile)SNV Pathogenic 186141 rs786202724 7:116417457-116417457 7:116777403-116777403
28 MTOR NM_004958.4(MTOR):c.4448G>T (p.Cys1483Phe)SNV Pathogenic 190121 rs786205165 1:11217230-11217230 1:11157173-11157173
29 FLCN NM_144997.7(FLCN):c.1429C>T (p.Arg477Ter)SNV Pathogenic 253251 rs879255678 17:17118502-17118502 17:17215188-17215188
30 NRAS NM_002524.5(NRAS):c.182A>C (p.Gln61Pro)SNV Pathogenic 280409 rs11554290 1:115256529-115256529 1:114713908-114713908
31 NRAS NM_002524.5(NRAS):c.183A>T (p.Gln61His)SNV Pathogenic 373003 rs121913255 1:115256528-115256528 1:114713907-114713907
32 PTEN NM_001304718.2(PTEN):c.-363C>GSNV Pathogenic 375958 rs121909224 10:89692904-89692904 10:87933147-87933147
33 VHL NM_001354723.2(VHL):c.*84_*90deldeletion Pathogenic 694389 3:10191534-10191540 3:10149850-10149856
34 MTOR NM_004958.4(MTOR):c.6644C>A (p.Ser2215Tyr)SNV Pathogenic/Likely pathogenic 376129 rs587777894 1:11184573-11184573 1:11124516-11124516
35 MTOR NM_004958.4(MTOR):c.4447T>C (p.Cys1483Arg)SNV Pathogenic/Likely pathogenic 374796 rs1057519914 1:11217231-11217231 1:11157174-11157174
36 NRAS NM_002524.5(NRAS):c.182A>T (p.Gln61Leu)SNV Pathogenic/Likely pathogenic 375874 rs11554290 1:115256529-115256529 1:114713908-114713908
37 PIK3CA NM_006218.4(PIK3CA):c.1633G>C (p.Glu545Gln)SNV Pathogenic/Likely pathogenic,drug response 375896 rs104886003 3:178936091-178936091 3:179218303-179218303
38 PIK3CA NM_006218.4(PIK3CA):c.1635G>T (p.Glu545Asp)SNV Pathogenic/Likely pathogenic 217293 rs121913275 3:178936093-178936093 3:179218305-179218305
39 TP53 NM_000546.5(TP53):c.824G>A (p.Cys275Tyr)SNV Pathogenic/Likely pathogenic 215997 rs863224451 17:7577114-7577114 17:7673796-7673796
40 FLCN NM_144997.7(FLCN):c.779+1G>TSNV Pathogenic/Likely pathogenic 231274 rs758175953 17:17125814-17125814 17:17222500-17222500
41 TP53 NM_000546.5(TP53):c.638G>C (p.Arg213Pro)SNV Pathogenic/Likely pathogenic 231214 rs587778720 17:7578211-7578211 17:7674893-7674893
42 TP53 NM_000546.5(TP53):c.527G>A (p.Cys176Tyr)SNV Pathogenic/Likely pathogenic 186451 rs786202962 17:7578403-7578403 17:7675085-7675085
43 MTOR NM_004958.4(MTOR):c.6644C>T (p.Ser2215Phe)SNV Pathogenic/Likely pathogenic 156703 rs587777894 1:11184573-11184573 1:11124516-11124516
44 TP53 NM_000546.5(TP53):c.842A>T (p.Asp281Val)SNV Pathogenic/Likely pathogenic 182968 rs587781525 17:7577096-7577096 17:7673778-7673778
45 PIK3CA NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys)SNV Pathogenic/Likely pathogenic 13655 rs104886003 3:178936091-178936091 3:179218303-179218303
46 MET NM_001127500.3(MET):c.3736G>A (p.Asp1246Asn)SNV Pathogenic/Likely pathogenic 13884 rs121913671 7:116423407-116423407 7:116783353-116783353
47 MET NM_001127500.3(MET):c.3743A>G (p.Tyr1248Cys)SNV Pathogenic/Likely pathogenic 13885 rs121913246 7:116423414-116423414 7:116783360-116783360
48 PIK3CA NM_006218.4(PIK3CA):c.1634A>G (p.Glu545Gly)SNV Pathogenic/Likely pathogenic 13656 rs121913274 3:178936092-178936092 3:179218304-179218304
49 TP53 NM_000546.5(TP53):c.844C>T (p.Arg282Trp)SNV Pathogenic/Likely pathogenic 12364 rs28934574 17:7577094-7577094 17:7673776-7673776
50 VHL NM_000551.3(VHL):c.319C>G (p.Arg107Gly)SNV Pathogenic/Likely pathogenic 43599 rs397516440 3:10183850-10183850 3:10142166-10142166

UniProtKB/Swiss-Prot genetic disease variations for Renal Cell Carcinoma, Nonpapillary:

73
# Symbol AA change Variation ID SNP ID
1 FLCN p.Arg239Cys VAR_066026 rs78683075
2 SETD2 p.Asn1733Asp VAR_069812
3 SETD2 p.Ser1769Pro VAR_069813
4 VHL p.Leu163Pro VAR_034998 rs28940297

Cosmic variations for Renal Cell Carcinoma, Nonpapillary:

9 (show top 50) (show all 7561)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM88579140 ZNF804A kidney,NS,carcinoma,clear cell renal cell carcinoma c.2363A>C p.Q788P 2:184937759-184937759 15
2 COSM88566796 ZNF804A kidney,NS,carcinoma,clear cell renal cell carcinoma c.121G>C p.E41Q 2:184866378-184866378 15
3 COSM100952565 ZNF800 kidney,NS,carcinoma,clear cell renal cell carcinoma c.719A>G p.N240S 7:127374617-127374617 15
4 COSM94790253 ZNF521 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3298A>G p.S1100G 18:25224620-25224620 15
5 COSM87583829 ZNF462 kidney,NS,carcinoma,papillary renal cell carcinoma c.7085G>A p.R2362Q 9:107003322-107003322 15
6 COSM137390699 ZNF423 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3559G>A p.V1187I 16:49626188-49626188 15
7 COSM151995781 ZNF281 kidney,NS,carcinoma,papillary renal cell carcinoma c.2093C>T p.P698L 1:200407613-200407613 15
8 COSM85326448 ZNF225 kidney,NS,carcinoma,papillary renal cell carcinoma c.1187G>T p.G396V 19:44131801-44131801 15
9 COSM105902090 ZNF142 kidney,NS,carcinoma,papillary renal cell carcinoma c.3811G>T p.D1271Y 2:218642705-218642705 15
10 COSM149301355 ZFHX3 kidney,NS,carcinoma,chromophobe renal cell carcinoma c.4509G>T p.Q1503H 16:72798173-72798173 15
11 COSM149268221 ZFHX3 kidney,NS,carcinoma,clear cell renal cell carcinoma c.745G>A p.G249S 16:72959401-72959401 15
12 COSM149269629 ZFHX3 kidney,NS,carcinoma,papillary renal cell carcinoma c.2590T>C p.Y864H 16:72957556-72957556 15
13 COSM149266502 ZFHX3 kidney,NS,carcinoma,clear cell renal cell carcinoma c.7052G>A p.C2351Y 16:72795630-72795630 15
14 COSM89411866 ZBTB2 kidney,NS,carcinoma,papillary renal cell carcinoma c.931G>A p.E311K 6:151366135-151366135 15
15 COSM152022098 YES1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.1069T>A p.L357I 18:739803-739803 15
16 COSM143036610 YAP1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.374C>G p.A125G 11:102114196-102114196 15
17 COSM87436198 XPO4 kidney,NS,carcinoma,papillary renal cell carcinoma c.1299C>A p.F433L 13:20809842-20809842 15
18 COSM101982001 XPO1 kidney,NS,carcinoma,papillary renal cell carcinoma c.259A>G p.I87V 2:61522653-61522653 15
19 COSM136040220 XKR7 kidney,NS,carcinoma,papillary renal cell carcinoma c.1409C>T p.T470M 20:31997126-31997126 15
20 COSM94289984 XIAP kidney,NS,carcinoma,clear cell renal cell carcinoma c.1001A>T p.K334M 23:123891261-123891261 15
21 COSM94289415 XIAP kidney,NS,carcinoma,renal cell carcinoma unclassified c.563G>C p.G188A 23:123886225-123886225 15
22 COSM96278984 WWP2 kidney,NS,carcinoma,clear cell renal cell carcinoma c.2056G>C p.E686Q 16:69936391-69936391 15
23 COSM91370315 WT1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.1432+1G>C p.? 11:32391971-32391971 15
24 COSM91379363 WT1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.536C>A p.P179H 11:32434810-32434810 15
25 COSM89581411 WNK3 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3809C>A p.T1270N 23:54238942-54238942 15
26 COSM101580971 WDR89 kidney,NS,carcinoma,papillary renal cell carcinoma c.260C>A p.S87* 14:63599683-63599683 15
27 COSM101322652 VWA8 kidney,NS,carcinoma,clear cell renal cell carcinoma c.1286A>G p.Q429R 13:41865963-41865963 15
28 COSM101325565 VWA8 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3300A>T p.E1100D 13:41701456-41701456 15
29 COSM96870566 VTCN1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.98-1G>T p.? 1:117156922-117156922 15
30 COSM94748869 VPS13B kidney,NS,carcinoma,clear cell renal cell carcinoma c.2580C>T p.Y860= 8:99274262-99274262 15
31 COSM88289499 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.388G>T p.V130F 3:10146561-10146561 15
32 COSM88290593 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.464-1G>A p.? 3:10149786-10149786 15
33 COSM88305492 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.291C>A p.P97= 3:10142138-10142138 15
34 COSM88291276 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.343C>T p.H115Y 3:10146516-10146516 15
35 COSM88303076 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.293A>T p.Y98F 3:10142140-10142140 15
36 COSM88289037 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.254T>C p.L85P 3:10142101-10142101 15
37 COSM88289748 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.525C>G p.Y175* 3:10149848-10149848 15
38 COSM88292344 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.286C>T p.Q96* 3:10142133-10142133 15
39 COSM88292485 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.241C>T p.P81S 3:10142088-10142088 15
40 COSM88307936 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.244C>T p.R82C 3:10142091-10142091 15
41 COSM88289384 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.263G>T p.W88L 3:10142110-10142110 15
42 COSM88290429 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.350G>T p.W117L 3:10146523-10146523 15
43 COSM88294468 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.473T>G p.L158R 3:10149796-10149796 15
44 COSM88292596 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.490C>T p.Q164* 3:10149813-10149813 15
45 COSM88292160 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.551T>C p.L184P 3:10149874-10149874 15
46 COSM88290922 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.345C>G p.H115Q 3:10146518-10146518 15
47 COSM88289274 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.194C>A p.S65* 3:10142041-10142041 15
48 COSM88292304 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.269A>T p.N90I 3:10142116-10142116 15
49 COSM88288882 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.203C>A p.S68* 3:10142050-10142050 15
50 COSM88305342 VHL kidney,NS,carcinoma,clear cell renal cell carcinoma c.492G>T p.Q164H 3:10149815-10149815 15

Copy number variations for Renal Cell Carcinoma, Nonpapillary from CNVD:

7 (show top 50) (show all 1298)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 14830 1 1104523 1105523 Gain Renal cell carcinoma
2 16766 1 13658511 13659511 Gain Renal cell carcinoma
3 16770 1 13703176 13704176 Loss Renal cell carcinoma
4 16773 1 13722829 13723829 Gain Renal cell carcinoma
5 19216 1 14925199 15393109 Loss Renal cell carcinoma
6 24428 1 180300000 185800000 Copy number Renal cell carcinoma
7 26325 1 199103044 199104044 Gain Renal cell carcinoma
8 27335 1 207179162 207180162 Gain Renal cell carcinoma
9 27861 1 214500000 224100000 Gain Renal cell carcinoma
10 30088 1 24000000 26000000 Loss Renal cell carcinoma
11 31042 1 24862824 24867531 Loss RCAN3 Renal cell carcinoma
12 31527 1 28000000 30200000 Loss Renal cell carcinoma
13 33893 1 5000000 7000000 Loss Renal cell carcinoma
14 42189 10 3000000 17300000 Copy number Renal cell carcinoma
15 42932 10 42300000 52900000 Copy number Renal cell carcinoma
16 49432 11 106916419 134173875 Loss Renal cell carcinoma
17 49705 11 110400000 121200000 Copy number Renal cell carcinoma
18 51840 11 13182721 13183721 Gain Renal cell carcinoma
19 51843 11 13184856 13185856 Loss Renal cell carcinoma
20 52861 11 21000000 57000000 Gain Renal cell carcinoma
21 53056 11 23642584 23643584 Gain Renal cell carcinoma
22 53595 11 31000000 43500000 Copy number Renal cell carcinoma
23 53953 11 35317771 35318771 Gain Renal cell carcinoma
24 60490 11 87000000 107000000 Gain Renal cell carcinoma
25 64438 12 12800000 14800000 Copy number Renal cell carcinoma
26 67031 12 35000000 69000000 Gain Renal cell carcinoma
27 67043 12 35400000 132349534 Gain Renal cell carcinoma
28 69398 12 54900000 58100000 Copy number Renal cell carcinoma
29 72532 12 82000000 100000000 Gain Renal cell carcinoma
30 75379 13 19500000 23300000 Loss Renal cell carcinoma
31 75593 13 21548578 21635655 Copy number Renal cell carcinoma
32 82801 14 15600000 106368585 Copy number Renal cell carcinoma
33 82818 14 15600000 106368585 Loss Renal cell carcinoma
34 83187 14 19387587 106241517 Loss Renal cell carcinoma
35 85229 14 41000000 48000000 Gain Renal cell carcinoma
36 87551 14 74550219 74587988 Loss MLH3 Renal cell carcinoma
37 88249 14 88692268 89155247 Loss FOXN3 Renal cell carcinoma
38 88312 14 89800000 91900000 Copy number Renal cell carcinoma
39 89170 15 100153615 100154615 Gain Renal cell carcinoma
40 90158 15 20233523 20234523 Gain Renal cell carcinoma
41 90187 15 20359182 20360182 Gain Renal cell carcinoma
42 90188 15 20359229 20360229 Gain Renal cell carcinoma
43 90209 15 20439260 20440260 Loss Renal cell carcinoma
44 90210 15 20442152 20442452 Loss Renal cell carcinoma
45 90214 15 20449913 20450913 Gain Renal cell carcinoma
46 90215 15 20450115 20451115 Loss Renal cell carcinoma
47 90218 15 20535877 20536877 Loss Renal cell carcinoma
48 90224 15 20611271 20612271 Loss Renal cell carcinoma
49 90229 15 20643792 20644792 Loss Renal cell carcinoma
50 90232 15 20666179 20666479 Loss Renal cell carcinoma

Expression for Renal Cell Carcinoma, Nonpapillary

Search GEO for disease gene expression data for Renal Cell Carcinoma, Nonpapillary.

Pathways for Renal Cell Carcinoma, Nonpapillary

Pathways related to Renal Cell Carcinoma, Nonpapillary according to KEGG:

36
# Name Kegg Source Accession
1 Renal cell carcinoma hsa05211
2 Transcriptional misregulation in cancer hsa05202

Pathways related to Renal Cell Carcinoma, Nonpapillary according to GeneCards Suite gene sharing:

(show all 42)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.8 VHL TP53 PTEN NRAS MTOR MET
2
Show member pathways
12.92 TP53 PTEN PIK3CA NRAS MTOR MET
3 12.78 VHL TP53 PTEN PIK3CA NRAS MTOR
4
Show member pathways
12.74 TP53 PTEN PIK3CA NRAS MTOR MET
5
Show member pathways
12.68 TP53 PTEN PIK3CA NRAS MTOR MET
6
Show member pathways
12.67 TP53 PTEN PIK3CA NRAS MTOR MET
7
Show member pathways
12.48 TP53 PIK3CA NRAS MTOR
8
Show member pathways
12.45 TP53 PTEN PIK3CA NRAS MTOR MET
9
Show member pathways
12.38 TP53 PIK3CA NRAS MTOR MET ATM
10
Show member pathways
12.37 TP53 PTEN PIK3CA MTOR MET
11 12.35 TP53 PIK3CA MTOR ATM
12
Show member pathways
12.33 TP53 PTEN PIK3CA NRAS MTOR MET
13
Show member pathways
12.31 VHL TP53 PTEN PIK3CA NRAS MTOR
14
Show member pathways
12.3 PTEN PIK3CA NRAS MTOR
15 12.29 TP53 PTEN PIK3CA NRAS ATM
16 12.23 TP53 PIK3CA NRAS MTOR MET
17
Show member pathways
12.17 TP53 PIK3CA NRAS MTOR
18
Show member pathways
12.16 TP53 PTEN PIK3CA NRAS MTOR MET
19 12.14 TP53 PTEN MTOR ATM
20
Show member pathways
12.12 TP53 PIK3CA NRAS MTOR
21 12.09 TP53 PTEN PIK3CA NRAS MTOR ATM
22
Show member pathways
12.08 PTEN PIK3CA NRAS ATM
23 12.07 PTEN PIK3CA NRAS MTOR
24
Show member pathways
12.04 TP53 NRAS MTOR ATM
25 12 TP53 PIK3CA NRAS MTOR
26 11.99 TP53 PTEN PIK3CA NRAS
27 11.95 TP53 PTEN NRAS MTOR
28 11.92 TP53 PTEN PIK3CA NRAS ATM
29
Show member pathways
11.87 PIK3CA MTOR HNF1B HNF1A
30 11.84 TP53 PTEN PIK3CA FHIT
31 11.79 TP53 PTEN MTOR
32 11.77 TP53 PTEN PIK3CA NRAS MTOR MIR200C
33 11.72 RNF139 PIK3CA MTOR
34
Show member pathways
11.71 TP53 MTOR ATM
35 11.71 TP53 PIK3CA ATM
36 11.59 TP53 SETD2 PTEN PIK3CA ATM
37 11.57 TP53 PTEN PIK3CA
38 11.49 TP53 PTEN ATM
39 11.38 NRAS MTOR MET
40 11.27 TP53 PTEN PIK3CA NRAS MTOR MET
41 11.26 NRAS MTOR MET
42 11.21 PTEN PIK3CA NRAS MTOR

GO Terms for Renal Cell Carcinoma, Nonpapillary

Biological processes related to Renal Cell Carcinoma, Nonpapillary according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.91 VHL TP53 PTEN OGG1 HNF1B
2 positive regulation of gene expression GO:0010628 9.72 TP53 PTEN MTOR HNF1B ATM
3 multicellular organism growth GO:0035264 9.65 TP53 MTOR ATM
4 response to glucose GO:0009749 9.58 PTEN HNF1B HNF1A
5 phosphatidylinositol-3-phosphate biosynthetic process GO:0036092 9.54 PIK3CA ATM
6 negative regulation of macroautophagy GO:0016242 9.52 PIK3CA MTOR
7 replicative senescence GO:0090399 9.49 TP53 ATM
8 anoikis GO:0043276 9.46 PIK3CA MTOR
9 negative regulation of cell size GO:0045792 9.43 PTEN MTOR
10 regulation of protein phosphorylation GO:0001932 9.43 PIK3CA MTOR FLCN
11 positive regulation of transcription initiation from RNA polymerase II promoter GO:0060261 9.37 HNF1B HNF1A
12 pancreas development GO:0031016 9.33 MET HNF1B HNF1A
13 regulation of pronephros size GO:0035565 8.96 HNF1B HNF1A
14 liver development GO:0001889 8.92 PIK3CA MET HNF1B HNF1A

Molecular functions related to Renal Cell Carcinoma, Nonpapillary according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleotide binding GO:0000166 9.35 NRAS MTOR MET FHIT ATM
2 1-phosphatidylinositol-3-kinase activity GO:0016303 9.26 PIK3CA ATM
3 transcription cofactor binding GO:0001221 9.16 TP53 HNF1A
4 protein-containing complex binding GO:0044877 9.02 NRAS MTOR HNF1B FLCN ATM

Sources for Renal Cell Carcinoma, Nonpapillary

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....